Targets › TRGC2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.
Constant region of T cell receptor (TR) gamma chain that participates in the antigen recognition. Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. (UniProt, P03986)
Open in Phaseline: the race on TRGC2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Kansas Medical Center | EAGD T-cell infusion (Expanded/Activated Gamma Delta T-cells) Gamma delta (γδ) T-cell immunotherapy enriched via α/β T-cell depletion | TRGC1, TRGC2 | Phase 1 | Acute Myeloid Leukemia | Jan 2027 |
Acute Myeloid Leukemia (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.